{"id":464509,"date":"2021-03-24T15:03:19","date_gmt":"2021-03-24T19:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464509"},"modified":"2021-03-24T15:03:19","modified_gmt":"2021-03-24T19:03:19","slug":"bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/","title":{"rendered":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm"},"content":{"rendered":"
\n

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Tyson Foods, Inc. (NYSE: TSN), Clover Health Investments Corp. (NASDAQ: CLOV, CLOVW), bluebird bio, Inc. (NASDAQ: BLUE), and EHang Holdings Limited (NASDAQ: EH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.<\/p>\n

\n Tyson Foods, Inc. (NYSE: TSN) <\/strong>\n <\/p>\n

Class Period: March 13, 2020 to December 15, 2020<\/p>\n

Lead Plaintiff Deadline: April 5, 2021<\/p>\n

On December 15, 2020, New York City Comptroller Scott M. Stringer (\u201cComptroller Stringer\u201d) called on the SEC to open an investigation into Tyson. In his letter to the SEC, Comptroller Stringer described Tyson\u2019s various failures to carry out its stated coronavirus protection policies.<\/p>\n

On this news, the price of Tyson shares fell $1.78 per share, or 2.5%, to close at $68.25 per share on December 15, 2020.<\/p>\n

The complaint, filed on February 2, 2021, alleges that defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) Tyson knew, or should have known, that the highly contagious coronavirus was spreading throughout the globe; (2) Tyson did not in fact have sufficient safety protocols to protect its employees in its facilities; (3) as a result, Tyson employees contracted and spread the coronavirus within the facilities; (4) as a result of the foregoing, Tyson would face negative impact to its production, including complete shutdowns of certain facilities; (5) due to the failure to protect its employees, Tyson would suffer financial harm related to its lowered production; and (6) as a result, defendants\u2019 public statements were materially false and\/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

For more information on the Tyson class action go to: https:\/\/bespc.com\/cases\/TSN<\/a><\/p>\n

\n Clover Health Investments Corp. (NASDAQ: CLOV, CLOVW)<\/strong>\n <\/p>\n

Class Period: Securities purchased between October 6, 2020 to February 4, 2021 and\/or pursuant or traceable to the Company\u2019s registration statement and prospectus issued in connection with the December 2020 Merger.<\/p>\n

Lead Plaintiff Deadline: April 6, 2021<\/p>\n

Clover Health provides healthcare insurance services and purports to use proprietary technology to collect, structure, and analyze health and behavioral data.<\/p>\n

On January 7, 2021, Clover merged with SPAC Social Capital Hedosophia Holdings Corp. III and Clover\u2019s common shares began trading on the NASDAQ under the ticker symbol \u201cCLOV,\u201d closing at $15.90 per share, and on January 11, Clover\u2019s redeemable warrants began trading on the NASDAQ under the ticker symbol \u201cCLOVW,\u201d closing at $3.36 per warrant.<\/p>\n

On February 4, 2021, Hindenburg Research issued a report stating that prior to the merger, Clover has been under active investigation by the U.S. Department of Justice for issues ranging from kickbacks to marketing practices to undisclosed third-party deals. Clover did not reveal that it was under active investigation by the DOJ.<\/p>\n

On this news, shares of Clover common shares (CLOV) plummeted from their February 3, 2021 closing price of $13.95 per share to close at $12.23 per share on February 4, 2021, and Clover warrants (CLOVW) fell $0.18 per warrant, to close at $3.39 per warrant on February 4, 2021.<\/p>\n

The complaint, filed on February 5, 2021, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company\u2019s business. Specifically, defendants made false and\/or misleading statements and\/or failed to disclose that: (i) Clover was the recipient of a Civil Investigative Demand from the DOJ; (ii) much of Clover\u2019s sales are driven by a major related party deal that Clover not only failed to disclose but took active steps to conceal; (iii) Clover\u2019s subsidiary Seek Insurance failed to disclose its relationship with Clover and misled consumers as to its purported independence; (iv) Clover\u2019s software was in fact rudimentary; and (v) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n

For more information on the Clover Health class action go to: https:\/\/bespc.com\/cases\/clover<\/a><\/p>\n

\n bluebird bio, Inc. (NASDAQ: BLUE)<\/strong>\n <\/p>\n

Class Period: May 11, 2020 and November 4, 2020<\/p>\n

Lead Plaintiff Deadline: April 13, 2021<\/p>\n

Bluebird is a biotechnology company that engages in researching, developing, and commercializing transformative gene therapies for severe genetic diseases and cancer. The Company\u2019s gene therapy programs include, among others, LentiGlobin (bb1111) for the treatment of sickle cell disease (\u201cSCD\u201d).<\/p>\n

In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application (\u201cBLA\u201d) to the U.S. Food and Drug Administration (\u201cFDA\u201d) for LentiGlobin for SCD in the second half of 2021.<\/p>\n

On November 4, 2020, bluebird disclosed that it would no longer apply for FDA approval of its LentiGlobin product as a treatment for SCD in the second half of 2021 as expected. Instead, citing \u201cfeedback\u201d from the FDA requiring the Company to provide additional data \u201cto demonstrate drug product comparability\u201d for LentiGlobin for SCD, \u201calongside COVID-19 related shifts and contract manufacturing organization COVID-19 impacts,\u201d bluebird adjusted its submission timing to late 2022.<\/p>\n

On this news, bluebird\u2019s stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.<\/p>\n

The complaint, filed on February 12, 2021, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company\u2019s business, operations, and compliance policies. Specifically, defendants made false and\/or misleading statements and\/or failed to disclose that: (i) data supporting bluebird\u2019s BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company\u2019s BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n

For more information on the bluebird bio class action go to: https:\/\/bespc.com\/cases\/Blue<\/a><\/p>\n

\n EHang Holdings Limited (NASDAQ: EH) <\/strong>\n <\/p>\n

Class Period: December 12, 2019 to February 16, 2021<\/p>\n

Lead Plaintiff Deadline: April 19, 2021<\/p>\n

On February 16, 2021, analyst Wolfpack Research published a scathing report entitled \u201cEHang: A Stock Promotion Destined to Crash and Burn.\u201d In this report, Wolfpack Research wrote that EHang is \u201can elaborate stock promotion, built on largely fabricated revenues based on sham sales contracts with a customer [Shanghai Kunxiang Intelligent Technology Co., Ltd. (\u201cKunxiang\u201d)] who appears to us to be more interested in helping inflate the value of its investment in EH . . . than about buying its products.\u201d Wolfpack Research wrote that it had \u201cgathered extensive evidence\u201d to support its report, \u201cincluding behind-the-scenes photographs, recorded phone calls, and videos of on-site visits to EH\u2019s various facilities . . . .\u201d Wolfpack Research also noted that \u201cin just 14 months as a publicly traded company, EH\u2019s PR team has put out 50 press releases . . . . However, EH\u2019s constant stream of press releases are easily proven untrue.\u201d Finally, Wolfpack Research wrote that it \u201cobtained Chinese court records which show that EH\u2019s ADRs may already be in serious jeopardy due to legal issues in China.\u201d<\/p>\n

On this news, the price of EHang\u2019s ADS fell from its February 12, 2021 close of $124.09 to a February 16, 2021 close of $46.30 per share, a one day drop of $77.79 per share or approximately 62.7%.<\/p>\n

The complaint, filed on February 17, 2021, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company\u2019s business. Specifically, defendants made false and\/or misleading statements and\/or failed to disclose that: (i) the Company\u2019s purported regulatory approvals in Europe and North American for its EH216 were for use as a drone, and not for carrying passengers; (ii) its relationship with its purported primary customer is a sham; (iii) EHang has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; (iv) the Company\u2019s manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees; and (v) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n

For more information on the EHang class action go to: https:\/\/bespc.com\/cases\/EH<\/a><\/p>\n

\n About Bragar Eagel & Squire, P.C.:<\/strong>
\n
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com<\/u><\/a>. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

\n Contact Information:<\/strong>
\n
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com<\/u><\/a>
www.bespc.com<\/a><\/u><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Tyson Foods, Inc. (NYSE: TSN), Clover Health Investments Corp. (NASDAQ: CLOV, CLOVW), bluebird bio, Inc. (NASDAQ: BLUE), and EHang Holdings Limited (NASDAQ: EH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Tyson Foods, Inc. (NYSE: TSN) Class Period: March 13, 2020 to December 15, 2020 Lead Plaintiff Deadline: April 5, 2021 On December 15, 2020, New York City Comptroller Scott M. Stringer (\u201cComptroller Stringer\u201d) called on the SEC … <\/p>\n

Continue reading “Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464509","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Tyson Foods, Inc. (NYSE: TSN), Clover Health Investments Corp. (NASDAQ: CLOV, CLOVW), bluebird bio, Inc. (NASDAQ: BLUE), and EHang Holdings Limited (NASDAQ: EH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Tyson Foods, Inc. (NYSE: TSN) Class Period: March 13, 2020 to December 15, 2020 Lead Plaintiff Deadline: April 5, 2021 On December 15, 2020, New York City Comptroller Scott M. Stringer (\u201cComptroller Stringer\u201d) called on the SEC … Continue reading "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-24T19:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm\",\"datePublished\":\"2021-03-24T19:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/\"},\"wordCount\":1471,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/\",\"name\":\"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg=\",\"datePublished\":\"2021-03-24T19:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/","og_locale":"en_US","og_type":"article","og_title":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm - Market Newsdesk","og_description":"NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Tyson Foods, Inc. (NYSE: TSN), Clover Health Investments Corp. (NASDAQ: CLOV, CLOVW), bluebird bio, Inc. (NASDAQ: BLUE), and EHang Holdings Limited (NASDAQ: EH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Tyson Foods, Inc. (NYSE: TSN) Class Period: March 13, 2020 to December 15, 2020 Lead Plaintiff Deadline: April 5, 2021 On December 15, 2020, New York City Comptroller Scott M. Stringer (\u201cComptroller Stringer\u201d) called on the SEC … Continue reading \"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-24T19:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm","datePublished":"2021-03-24T19:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/"},"wordCount":1471,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/","name":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg=","datePublished":"2021-03-24T19:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTc5MiM0MDg5OTI4IzIxMDAzOTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-tyson-foods-clover-health-investments-bluebird-bio-and-ehang-and-encourages-investors-to-contact\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tyson Foods, Clover Health Investments, bluebird bio, and EHang and Encourages Investors to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464509"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464509\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}